AzurRx BioPharma reports positive results in its Phase 2a trial of pancreatitis drug

MS1819-SD was developed to treat exocrine pancreatic insufficiency caused by chronic pancreatitis

AzurRx BioPharma Inc (NASDAQ:AZRX) announced a successful Phase 2a trial study of its pancreatitis drug.

MS1819-SD is designed to treat exocrine pancreatic insufficiency caused by chronic pancreatitis, a disease characterized by inflammation of the pancreas.

READ: Trevena shares pop on successful completion of Phase 1 study of acute migraine treatment

Initial data from the study shows a “very strong safety and efficacy profile”, according to the company’s press statement.

The Brooklyn-based biopharma will look into applying the drug to the treatment of cystic fibrosis as well.

“Based on these data, we believe we have the basis for initiating a Phase IIb trial of MS1819 in cystic fibrosis patients in the fall of 2018,” said Chief Medical Officer James Pennington in a statement.

The biopharma specializes in the development of non-systemic, recombinant therapies for gastrointestinal diseases. While MS1819 is its lead drug candidate, it is also conducting early-stage research into the prevention of hospital-acquired infections.

Shares jumped nearly 8% to US$3.16 in Friday morning trading.


Featured Posts
Recent Posts
Search By Tags

Support Zahra's run for Palestine CF patients.

  • Facebook Clean
  • Twitter Clean
  • Instagram - Grey Circle
  • YouTube - Grey Circle
  • LinkedIn Clean